Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Eli Lilly's Forsteo for osteoporosis in men approved by European Commission

July 26, 2007

Positive results for Advanced Magnetics' fourth phase III trial of ferumoxytol

July 26, 2007

PF-429242: Example of novel S1P inhibitors for dyslipidemia and related disorders

July 25, 2007

Wyeth receives approvable letter for Pristiq in menopause-related vasomotor symptoms

July 25, 2007

Tercica completes clinical trial enrollment for Increlex in pediatric primary IGFD

July 25, 2007

Forbes Medi-Tech on track for corporate objectives and revenue growth

July 25, 2007

Interim data from Bone Medical's phase II trial of Capsitonin capsules

July 24, 2007

LG Life Sciences synthesizes novel, potent DPP-IV inhibitors

July 23, 2007

CHMP recommends E.U. approval of Aclasta for postmenopausal osteoporosis

July 23, 2007

Galvus receives European recommendation for approval

July 23, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...